Connor Clark & Lunn Investment Management Ltd. raised its stake in Health Catalyst, Inc. (NASDAQ:HCAT – Free Report) by 118.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 131,532 shares of the company’s stock after acquiring an additional 71,201 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.22% of Health Catalyst worth $1,071,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Principal Financial Group Inc. raised its holdings in shares of Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after acquiring an additional 1,907 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after acquiring an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after acquiring an additional 2,164 shares during the last quarter. Creative Planning raised its holdings in shares of Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after acquiring an additional 2,486 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.
Health Catalyst Price Performance
Shares of NASDAQ HCAT opened at $8.65 on Thursday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The business has a 50-day moving average of $8.13 and a 200-day moving average of $7.30. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market capitalization of $526.34 million, a price-to-earnings ratio of -6.41 and a beta of 1.32.
Insider Buying and Selling
In related news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the transaction, the chief operating officer now owns 129,690 shares in the company, valued at approximately $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up from $11.00) on shares of Health Catalyst in a research note on Tuesday. Stephens upped their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Citigroup upped their target price on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.79.
View Our Latest Report on HCAT
Health Catalyst Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Recommended Stories
- Five stocks we like better than Health Catalyst
- CD Calculator: Certificate of Deposit Calculator
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the Dogs of the Dow Strategy? Overview and Examples
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Earnings Per Share Calculator: How to Calculate EPS
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.